Alcista
$115.77
Precio del escenario
$172.970
-2.543 (-1.47%)Al cierre
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $172.97, and the company has a forward P/E ratio of 23.87, indicating reasonable valuation compared to its growth prospects. Additionally, the gross margin has improved to 55.54%, showcasing operational efficiency. Analyst targets range from $165 to $195, with the average target suggesting a potential upside of over 12% from the current price. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which could impact future revenue growth.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Agilent Launches CE-IVD Labeled TapeStationDx Systems for Clinical Labs

Multiple Companies Announce Quarterly Cash Dividends

Agilent Technologies Announces Quarterly Dividend

Agilent Launches S540MD Slide Scanner System in U.S.

Agilent Launches S540MD Slide Scanner System in the U.S.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $172.97, and the company has a forward P/E ratio of 23.87, indicating reasonable valuation compared to its growth prospects. Additionally, the gross margin has improved to 55.54%, showcasing operational efficiency. Analyst targets range from $165 to $195, with the average target suggesting a potential upside of over 12% from the current price. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which could impact future revenue growth.
$APR has dropped over thirty points, a sharp breakdown. On the chart, price has sliced straight through the lower Bollinger Band, the MACD death cross is still widening downward, the green bars show no sign of shrinking, and rebounds are firmly capped by the supertrend line. This move shows capital is exiting in a stampede, not even trying to hide it anymore. In the short term, anyone who touches this gets hurt, and bottom-fishing is out of the question. $A fell nearly fourteen points and is also heading toward the lower Bollinger Band. It is dying the same way as those high-flying coins from a while back: there may have been some heat early on, but once overall market sentiment weakens, profit-takers run faster than rabbits. The MACD has now death-crossed at a high level, momentum has turned fully bearish, and in this search for support, every rebound halfway down is just there to trap more bottom-fishers. $BILL dropped more than twelve points, also grinding lower all the way to the bottom. The decline is relatively smaller, but look at its chart structure: price is pressing toward the lower band, MACD is weak and pointing down, the supertrend line is capping it, and there is no signal of stabilization at all. This shows capital is withdrawing in an orderly way, and no funds are willing to support this level. The current macro environment does not allow blind bottom-fishing at all. Market confidence is extremely fragile, and these small-cap and sentiment-driven plays have no cushion whatsoever. Anyone catching this falling knife is just giving money away. #VolatilityRadar: Coin Movement Watch
Mostrar más$MHA $A $CYS I used to think copy trading was just another trend that sounded better than it actually was, so I kept ignoring it. Looking back, that was probably one of my biggest mistakes. I eventually decided to give Alyssa Tan's market insights a chance and started with $3,750. I didn't expect much, I just wanted a more disciplined approach to trading. Three months later, I've already accumulated over $96,800 in profits, and I've learned far more about risk management and market timing than I ever did trying to figure everything out on my own. I'm genuinely grateful to everyone who kept recommending Alyssa Tan. If I hadn't finally reached out, I don't think I would have realized how valuable her guidance truly is. Taking that step turned out to be one of the best decisions I've made in my trading journey.
Mostrar más
$BinanceBee Liangxi has issued another token! It's getting more and more like a cash grab. Truly shameless. All the good reputation from before has been used to harvest retail investors.
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.